#### 1 Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of

#### 2 COVID-19 infection

- 3 Ahava MJ<sup>1</sup>, Kurkela S<sup>1</sup>, Kuivanen S<sup>2</sup>, Lappalainen M<sup>1</sup>, Jarva H<sup>1,3</sup>, Jääskeläinen AJ<sup>1</sup>
- <sup>4</sup> <sup>1</sup>HUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and
- 5 Helsinki University Hospital, Finland
- <sup>6</sup> <sup>2</sup>Department of Virology, University of Helsinki, Helsinki, Finland
- 7 <sup>3</sup>Translational Immunology Research Program and Department of Bacteriology and
- 8 Immunology, University of Helsinki, Helsinki, Finland
- 9 Corresponding author: Maarit J Ahava, maarit.ahava@hus.fi, Tel: +358 9 4711, Helsinki
- 10 University Hospital, HUSLAB, Virology and Immunology, P.O.B. 720 (Topeliuksenkatu
- 11 32), FI-00029 HUS, Finland.
- **12** Word count: 1276

13

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 14 Abstract

15	SARS-CoV-2 RNA can be detected in respiratory samples for weeks or even months after
16	onset of COVID-19 disease. Therefore, one of the diagnostic challenges of PCR positive
17	cases is differentiating between acute COVID-19 disease and convalescent phase. Recently,
18	the presence of SARS-CoV-2 nucleocapsid antigen in serum samples of COVID-19 patients
19	was published [Le Hingrat et al. Detection of SARS-CoV-2 N-antigen in blood during acute
20	COVID-19 provides a sensitive new marker and new testing alternatives, Clinical
21	Microbiology and Infection, 2020].
22	Our study aimed to characterize the analytical specificity and sensitivity of an enzyme-linked
23	immunosorbent assay (Salocor SARS-CoV-2 Antigen Quantitative Assay Kit <sup>©</sup> (Salofa Ltd,
24	Salo, Finland)) for the detection of SARS-CoV-2 antigen in serum, and to characterize the
25	kinetics of antigenemia. The evaluation material included a negative serum panel of 155
26	samples, and 126 serum samples from patients with PCR-confirmed COVID-19.
27	The specificity of the Salocor SARS-CoV-2 serum N antigen test was 98.0%. In comparison
28	with simultaneous positive PCR from upper respiratory tract (URT) specimens, the test
29	sensitivity was 91.7%. In a serum panel in which the earliest serum sample was collected two
30	days before the collection of positive URT specimen, and the latest 48 days after (median 1
31	day post URT sample collection), the serum N antigen test sensitivity was 94% within 14
32	days post onset of symptoms. The antigenemia resolved approximately two weeks after the
33	onset of disease and diagnostic PCR.
34	The combination of simultaneous SARS-CoV-2 antigen and antibody testing appeared to
35	provide useful information for the timing of COVID-19. Our results suggest that SARS-CoV-
36	2 N-antigenemia may be used as a diagnostic marker in acute COVID-19.

37

# 38 Introduction

39 SARS-CoV-2 laboratory diagnostics relies primarily on molecular diagnostic techniques [1-

40 3]. More recently, a variety of tests for SARS-CoV-2 antigen detection from upper

41 respiratory tract (URT) specimens have established a complementary role [4]. While less

42 sensitive, they benefit from being rapid, cheap, and performable outside centralized

43 laboratory facilities.

44 Recent articles and preprints demonstrate SARS-CoV-2 nucleocapsid (N) antigenemia in

45 COVID-19 patients [5,6]. While posing new questions on the pathophysiology of acute

46 COVID-19, this may offer a novel diagnostic approach. Only limited information is available

47 on the performance of serum antigen tests as a diagnostic method for SARS-CoV-2.

48 The aim of this study was to characterize the analytical specificity and sensitivity of an

49 enzyme-linked immunosorbent assay (ELISA) for the detection of SARS-CoV-2 antigen in

50 serum, namely Salocor SARS-CoV-2 Antigen Quantitative Assay Kit<sup>©</sup> (Salofa Ltd, Salo,

51 Finland; later Salocor N-antigen EIA) and to characterize the kinetics of antigenemia.

#### 52 Materials and methods

53 Serum samples were originally sent for diagnostic purposes to the Department of Virology

54 and Immunology, Helsinki University Hospital Laboratory HUSLAB, Finland. Research

permit HUS/157/2020-44 (Helsinki University Hospital, Finland) was obtained from the local
review board.

57 The negative panel (N=155; 148 cases) consisted of 144 serum samples collected in 2019,

and 11 samples (positive for Aspergillus antigen) in 2020. Of the 155 specimens, 37 were

sent for respiratory virus antibody testing; 32 samples were positive for anti-nuclear

60 antibodies; 16 for phospholipase-A2-receptor antibodies; 8 for antineutrophil cytoplasmic (C-

ANCA, P-ANCA and parallel C- and P-ANCA), and 4 for glomerular basement membrane
antibodies. Two samples were from patients with Human coronavirus (HCoV) OC43
diagnosis (by PCR) and five with primary Epstein-Barr virus (EBV) infection. We also
included serum specimens with a positive microbial antigen test as follows: 22 with Dengue
virus NS1 antigen, 17 with hepatitis B virus surface antigen, 11 with Aspergillus antigen, and
one with HIV p24 antigen. The median age of the negative panel cases was 53 years (range 289); 45% were males (66/148).

68 There were two separate serum specimen panels from PCR confirmed COVID-19 patients

69 (panel A and panel B), who were previously SARS-CoV-2 PCR positive from a URT

70 specimen. They were also tested for SARS-CoV-2 IgG by both Abbott SARS-CoV-2 IgG (N

antigen) and Euroimmun SARS-CoV-2 IgG (S1 antigen) according to manufacturer's

72 instructions.

Panel A comprised 70 serum samples from 62 cases (median age 54 years, range 24-86 years;

74 28/62 (45%) males). The earliest serum sample was collected 2 days before the collection of

the positive URT specimen, and the latest 48 days after (median 1 day post URT sample

collection). The samples were previously tested with SARS-CoV-2 microneutralization

(MNT) [7]. The date of onset of symptoms was available for 55/62 cases. Adjusted p-values

78 for comparison of antigen and MNT result combinations were determined using Kruskal-

79 Wallis test (GraphPad Prism 8.0.1).

Panel B comprised 56 serum samples from 27 cases (median age 50 years, range 27-65 years;

81 4/27 males); 2-4 consecutive serum samples from each. At least one serum from all 27 cases

82 was SARS-CoV-2 IgG positive in both Abbott and Euroimmun tests. The earliest serum

sample was collected 5 days before the collection of the positive URT specimen, and the

- 84 latest 207 days after (median 101 days post URT specimen collection). The date of onset of
- symptoms and MNT result were not available for this panel.
- 86 The PCR tests were carried out with one of the following methods: a laboratory-developed
- 87 test based on Corman et al.; cobas® SARS-CoV-2 test kit on the cobas® 6800 system (Roche
- 88 Diagnostics, Basel, Switzerland); and the Amplidiag® COVID-19 test on the Amplidiag®
- 89 Easy platform (Mobidiag, Espoo, Finland). The performance of these tests in our laboratory
- 90 is reported elsewhere [8].
- 91 The here-evaluated Salocor N-antigen ELISA (Salofa) is based on a double antibody
- sandwich ELISA test. The assay protocol is described in the Supplement.
- 93 The 95% Clopper-Pearson confidence intervals were calculated for sensitivity and specificity
- 94 (IBM SPSS statistical program package, version 25).

# 95 **Results**

96 The specificity of the Salocor N antigen ELISA was 98.0% (145/148) (Clopper-Pearson 95%

97 confidence interval 94.2-99.6%) as determined by the negative panel. The three positive

samples were collected in 2019. One was from a patient with EBV primary infection (5

99 pg/ml). Two were originally sent for respiratory virus antibody screening; one with reported

100 myocarditis (84.5 pg/ml) and one without any reported clinical outcome (4 pg/ml).

101 There was a simultaneous serum and PCR positive URT specimen available in 24 cases: N

antigen was positive in 22/24, rendering 91.7% sensitivity (Clopper-Pearson 95% confidence

103 interval 73.0-99.0%). The negative specimens were retrieved at one day and at 16 days post

- 104 disease onset. The PCR cycle threshold values did not appear to associate with the N antigen
- 105 concentrations (Figure 1a).

106	Using COVID-19 panel A, we calculated test sensitivity in relation to disease onset (Table 1).
107	The sensitivity with specimens retrieved at $\leq 14$ days post onset was 94%, and decreased to
108	50% with specimens retrieved 15-21 days post onset (Table 1). The N antigen concentrations
109	decreased over time from symptom onset (Figure 1b). The furthest time point for a positive N
110	antigen was observed at 47 days post disease onset (3.5 pg/ml) (Figure 1b).
111	The median days from disease onset for subgroups in panel A were as follows: N antigen
112	positive (≥2.97 pg/ml), MNT antibody negative (<40 titer) (6 days; 25 cases); N antigen
113	positive, MNT antibody positive (10 days; 31 cases); N antigen negative, MNT antibody
114	positive (37 days; 10 cases) (Figure 2).
115	There appeared to be a decreasing trend in N antigen concentration over increasing
116	Euroimmun anti-S1 IgG test result (Figure 1c), but no such trend was observed over
117	increasing Abbott anti-N IgG test result (Figure 1d), nor the increasing MNT titer (Figure 1e).
118	Of the COVID-19 panel B, the only N antigen positive serum was retrieved on the date of
119	positive PCR. All other 69 panel B serum specimens were N antigen negative; one was
120	retrieved 5 days before positive PCR in URT, and the others between 12 and 207 days
121	(median 107 days) after positive PCR in URT.
122	Discussion

- 123 SARS-CoV-2 RNA can be detected for even 4-6 weeks post disease onset in URT samples
- 124 [9,10]. Subsequently, one of the challenges in contact tracing of PCR positive cases is
- differentiating between acute COVID-19 disease and convalescent phase. The present study
- 126 brings forward a potential tool to aid in timing of COVID-19 disease: detection of SARS-
- 127 CoV-2 N antigen in serum.

128 Only two previous reports are available on SARS-CoV-2 antigen detection in serum [5,6]. Some antigen tests for the detection of SARS-CoV have been described [11,12]. We showed 129 a very good specificity (98.0%), and a reasonable sensitivity (91.7%; in comparison with 130 131 simultaneous positive PCR from URT specimens) for the Salocor N antigen test. SARS-CoV-2 N antigenemia appeared to resolve within the first two weeks of illness. Particularly the 132 combination of simultaneous SARS-CoV-2 antigen and antibody testing may provide useful 133 134 information for timing of disease (Figure 2). These tests can be performed from a single serum specimen in high throughput platforms. While this approach does not replace detection 135 136 of SARS-CoV-2 RNA from URT, it may provide an additional aid. 137 Only a limited number of serum specimens was available with information on disease onset, particularly for the convalescent phase. This diminishes the ability of this study to provide a 138 complete timeline for antigenemia in COVID-19. Potential cross-reactivity with seasonal 139 140 coronaviruses was not assessed in our study. 141 More data is needed to clarify whether serum N antigen testing could be used to supplement 142 current testing strategies for acute COVID-19. One interesting question is whether there is an association between antigenemia and viral shedding. Besides diagnostic differentiation 143 between acute and convalescent COVID-19, N antigen testing from serum could potentially 144 be deployed in epidemiological screening of asymptomatic infections, e.g. in recently 145 vaccinated populations. 146

- 147
- 148
- 149
- 150

## 152 Acknowledgements

- 153 We would like to thank Marita Koivunen (HUS Diagnostic Center, HUSLAB, Helsinki,
- 154 Finland), Eliisa Kekäläinen (Hus Diagnostic Center and University of Helsinki, Helsinki
- 155 Finland) and Jesper Kivelä (Hus Diagnostic Center and University of Helsinki, Helsinki
- 156 Finland).
- 157 Author contributions: MJA: Conceptualization, Investigation, Data curation, Writing -
- 158 original draft, SKU: Conceptualization, Formal analysis, Resources, Writing original draft,
- 159 Writing review and editing, Supervision, Project administration, SK: Investigation, Writing
- 160 –review and editing, ML: Resources, Writing review and editing, Supervision, Project
- 161 administration HJ: Conceptualization, Formal analysis, Visualization, Resources, Writing –
- 162 review and editing, Supervision, Project administration, AJJ: Conceptualization,
- 163 Investigation, Formal analysis, Data curation, Writing original draft, Supervision, Project
- 164 administration
- 165 *Potential conflicts of interest:* Authors report no conflict of interest.
- 166 *Funding:* This work has been supported by Helsinki University Hospital (TYH2019263).

167

168

### 170 **References**

- 171 [1] Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV)
- by real-time RT-PCR. *Euro Surveillance*. 2020;25(3):01.
- 173 [2] Kubina R, Dziedzic A. Molecular and Serological Tests for COVID-19 a Comparative
- 174 Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics.
- 175 *Diagnostics*. 2020;10(6):434. doi:10.3390/diagnostics10060434.
- 176 [3] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
- 177 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
- 178 Review. JAMA. 2020;324(8):782-793. doi:10.1001/jama.2020.12839.
- 179 [4] D'Cruz RJ, Currier AW, Sampson VB. Laboratory Testing Methods for Novel Severe
- 180 Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Front Cell Dev Biol.
- 181 2020;8:468. doi:10.3389/fcell.2020.00468.
- 182 [5]Le Hingrat QL, Visseaux B, Laouenan C, et al. Detection of SARS-CoV-2 N-antigen in
- 183 blood during acute COVID-19 provides a sensitive new marker and new testing
- alternatives. *Clin Microbiol Infect.* 2020. doi:10.1016/j.cmi.2020.11.025.
- 185 [6] Lebedin Y, Lyang O, Galstyan A, Belousov V, Rebrikov D. Serum SARS-CoV-2
- 186 nucleocapsid antigen detection is essential for primary diagnostics of SARS-CoV-2
- associated pneumonia. *medRxiv*. 2020. doi:10.1101/2020.09.24.20200303.
- 188 [7] Jaaskelainen AJ, Kuivanen S, Kekalainen E, et al. Performance of six SARS-CoV-2
- immunoassays in comparison with microneutralisation. *J Clin Virol*. 2020;129:104512.
- 190 doi:S1386-6532(20)30254-7 [pii].
- 191 [8] Mannonen L, Kallio-Kokko H, Loginov R, et al. Comparison of two commercial
- 192 platforms and a laboratory developed test for detection of SARS-CoV-2 RNA. *medRxiv*.
- 193 2020. doi:10.1101/2020.07.03.20144758.

- 194 [9] Hong K, Cao W, Liu Z, et al. Prolonged presence of viral nucleic acid in clinically
- 195 recovered COVID-19 patients was not associated with effective infectiousness. *Emerg*
- 196 *Microbes Infect.* 2020;9(1):2315-2321. doi:10.1080/22221751.2020.1827983.
- 197 [10] Kim S, Hwang YJ, Kwak Y. Prolonged SARS-CoV-2 detection and reversed RT-PCR
- 198 results in mild or asymptomatic patients. *Infect dis.* 2020;
- doi:10.1080/23744235.2020.1820076.
- 200 [11] Che X, Hao W, Wang Y, et al. Nucleocapsid Protein as Early Diagnostic Marker for
- 201 SARS. *Emerg Infect Dis.* 2004;10(11):1947-1949. doi:10.3201/eid1011.040516.
- 202 [12] Cho S, Woo H, Kim K, Oh J, Jeong Y. Novel system for detecting SARS coronavirus
- nucleocapsid protein using an ssDNA aptamer. *J Biosci Bioeng*. 2011;112(6):535-540.
- doi:10.1016/j.jbiosc.2011.08.014.

205

206

#### 

#### **Table 1** Sensitivity of serum antigen test in relation to time post symptom onset

	Time post symptom		
Time post symptom	onset (days, mean		Sensitivity (%
onset (days)	[SD])	Ν	[CI 95%] <sup>a</sup> )
≤7	4.6 (2.3)	26	96.2 (80.4-99.9)
8-14	10.4 (1.7)	24	91.7 (73.0-99.0)
≤14	7.4 (3.5)	50	94.0 (83.5-98.7)
15-21	16.3 (1.9)	6	50.0 (11.8-88.2)
≤21	8.4 (4.4)	56	89.3 (78.1-96.0)
≥7	16.2 (12.5)	41	75.6 (59.7-87.6)
≥14	28.6 (14.9)	14	42.9 (17.7-71.1)
≥21	41.1 (10.3)	7	28.6 (3.7-71.0)

<sup>a</sup>Clopper-Pearson confidence interval 

# 213 Figure legends

214	Figure 1. Serum antigen concentrations in relation to the timing of sampling and other tests.
215	Serum antigen concentrations of >180 pg/ml are depicted as 180 pg/ml. A. Serum antigen
216	concentrations compared to the Ct-value of a URT PCR sample obtained on the same day. B.
217	Serum antigen concentrations relative to the timing of sampling after the onset of symptoms.
218	C. Correlation of serum antigen concentration with the Euroimmun IgG assay results. The
219	vertical line indicates the cut-off value of the Euroimmun assay D. Antigen concentrations in
220	comparison with the Abbott IgG assay results. The vertical line indicates the cut-off value of
221	the Abbott assay E. Serum antigen concentrations relative to the microneutralization test titer.
222	MNT titers of <40 (negative) are depicted as 0 and MNT titers of >2560 as 2560. Figure
223	created using GraphPad Prism 8.0.1 software.
224	
225	Figure 2 Simultaneous N antigen and MNT test results in relation to symptom onset. N
226	antigen positive and MNT negative, median 6 days. N antigen positive, MNT positive,
227	median 10 days. N antigen negative and MNT positive median. 37 days. Adjusted p-values
228	(Kruskal-Wallis test): *p=0.0317; **p 0.0015, and ***p=<0.0001. Figure created using

- 229 GraphPad Prism 8.0.1 software.
- 230
- 231
- 232
- 233

Figure 1



#### 236 Figure 2

